

Deepak Nitrite (DN IN)

**Q1FY27 Result
Update**

August 06, 2026

☒ Estimate Change | ☒ Target | ☐ Reco.

Change in Estimates

	Current		Previous	
	FY27E	FY28E	FY27E	FY28E
Rating	REDUCE		REDUCE	
Target Price	1,586		1,514	
Sales (INR mn)	93,830	102,210	86,273	99,775
% Chng.	8.8	2.4		
EBITDA (INR mn)	14,580	14,879	11,049	13,410
% Chng.	32.0	11.0		
EPS (INR)	61.8	54.6	43.4	48.8
% Chng.	42.4	11.9		

Key Data

DPNT.BO | DN IN

BSE Code	506401
NSE Code	DEEPAKNTR
52-W High / Low	INR 1,904 / INR 1,280
Face Value	2
Sensex / Nifty	78,955 / 24,636
Market Cap	INR 239 bn / \$ 2,507 mn
Shares Outstanding	136.39 mn
3M Avg. Daily Value	INR 432.76 mn

Shareholding Pattern (%)

Promoters	49.34
FII's	6.25
Mutual Funds	11.45
Domestic Institutions	12.31
Public & Others	20.65
Promoter's Pledge (INR bn)	-

Stock Performance (%)

	1M	3M	6M	12M
Absolute	9.2	(3.9)	8.2	(3.4)
Relative	8.3	(5.1)	14.6	(1.5)

Key Financials - Consolidated

Y/e Mar	FY25	FY26	FY27E	FY28E
Sales (INR mn)	82,819	78,871	93,830	102,210
EBITDA (INR mn)	10,918	9,807	14,580	14,879
Margin (%)	13.2	12.4	15.5	14.6
PAT (INR mn)	6,974	5,379	8,431	7,460
EV (INR mn)	247,640	252,352	274,923	296,817
Total Debt (INR mn)	12,591	16,287	40,000	60,000
C&C Eq. (INR mn)	4,066	2,690	3,831	1,938
EPS (INR)	51.1	39.4	61.8	54.7
Gr. (%)	(14.0)	(22.9)	56.7	(11.5)
DPS (INR)	8.0	5.0	7.7	6.8
Yield (%)	0.4	0.3	0.4	0.4
RoE (%)	13.7	9.6	13.6	10.8
RoCE (%)	15.4	10.7	13.1	9.3
EV/Sales (x)	3.0	3.2	2.9	2.9
EV/EBITDA (x)	22.7	25.7	18.9	19.9
PE (x)	34.2	44.4	28.3	32.0
P/BV (x)	4.4	4.1	3.6	3.3

Improved spreads drive margin expansion

Quick Pointers

- MIBK and MIBC commissioning expected in August
- The company plans to debottleneck phenol capacity to nearly 400ktpa

Deepak Nitrite reported Q1FY27 revenue of INR25.8bn, up 36.4% YoY and 21.6% QoQ. Reported revenue included an incentive of INR215mn for the Phenolics segment from the Government of Gujarat, compared with INR172mn in Q1FY26. The Advanced Intermediates segment reported revenue of INR8bn, up 33% YoY, while EBIT increased 89% YoY and 100% QoQ to INR670mn, supported by backward integration benefits and an improving product mix. The Phenolics segment delivered its best-ever quarterly performance, with revenue of INR17.8bn, up 36% YoY and 24% QoQ, while EBIT surged 254% YoY to INR4.18bn. EBIT margin expanded sharply to 23.5%, driven by a significant improvement in phenol-acetone spreads amid supply disruptions caused by the West Asia crisis. On the capex front, the company expects to commission the MIBK, MIBC, and Acetophenone projects in August, while the multi-purpose agrochemical intermediates facility is scheduled to be commissioned during Q2FY27. The Polycarbonate project also remains on track for commissioning in H2FY29.

DN continues to pursue multiple growth initiatives, primarily focused on expanding its Phenolics portfolio. However, our analysis indicates that global phenol overcapacity remains a structural concern, while the elevated phenol-acetone spreads have already begun moderating on a week-on-week basis. As supply conditions normalize, we expect spreads and margins to gradually revert. The stock is currently trading at ~32x FY28E EPS. We value the company at 29x FY28E EPS and maintain our 'REDUCE' rating with a target price of INR1,586.

Consolidated revenue increases by 36.4% YoY and 21.6% QoQ: Deepak Nitrite consolidated revenue stood at Rs25.8bn (36.4% YoY/ 21.6% QoQ; PLe: Rs21.7bn, Consensus: Rs23.1bn), increased driven by 33% and 36% YoY increased in Advance intermediate segment and Phenolics segment revenue respectively.

EBITDA increases by 185% YoY and 44%QoQ: EBITDA stood at Rs5.4bn, increased by 185% YoY and 44% QoQ (vs Rs1.9bn in Q1FY26 and Rs3.8bn in Q4FY26). EBITDA margin came at 21% (vs 10% in Q1FY26 and 17.7% in Q4FY26; PLe: 16.5%). Gross profit margin was 37% (vs 28% in Q1FY26 and 35% in Q4FY26; PLe: 33.2%).

Quarter Summary

Y/e Mar	Q1'27E	Q1'27A	% Var.	Q1'26A	YoY gr. (%)
Net Sales (INR mn)	21,737	25,776	18.6	18,899	36.4
EBITDA (INR mn)	3,587	5,402	50.6	1,896	185.0
Margin (%)	16.5	21.0	446 bps	10.0	1093 bps
PAT (INR mn)	2,306	3,450	49.6	1,123	207.4

Source: Company, PL

Swarnendu Bhushan

swarnendubhushan@plindia.com | +91-22-66322260

Saurabh Ahire

saurabhahire@plindia.com | +91-22-66322537

Tejas Kadam

tejaskadam@plindia.com | +91-22-66322556

Segmental mix: Phenolics accounted for 69% of total revenue in Q1FY27, with EBIT/kg improving to INR21.5 compared to INR16.5 in Q4FY26. During the quarter, the segment received a government incentive of INR215mn for Deepak Phenolics, compared to INR684mn in Q4FY26. Advanced Intermediates contributed 31% of total revenue and reported an EBIT margin of 8.3%, compared to 4.7% in Q4FY26. Overall, Phenolics contributed 86% of total EBIT, while Advanced Intermediates accounted for the remaining 14%. Excluding the government incentive, the Phenolics segment reported an adjusted EBIT margin of 22.6% in Q1FY27 versus 16.0% in Q4FY26, while adj EBIT/kg improved to INR20.4 from INR12.5 in the previous quarter, driven by higher better product spreads, and improved manufacturing efficiencies.

Concall takeaways: (1) Q1FY27 performance was driven by improved demand across key end markets, higher manufacturing efficiencies, and integration benefits. (2) The Phenolics segment delivered its highest-ever quarterly performance, while the Advanced Intermediates business benefited from backward integration, improved product mix, and better operating leverage. (3) The company remains on track with its growth capex. MIBK, MIBC, and Acetophenone projects are scheduled for commissioning in this month, while the multi-purpose agrochemical intermediates facility is expected to be commissioned during Q2FY27. (4) The integrated polycarbonate project is progressing as planned. The company has already qualified polycarbonate compounds with key customers including Mahindra, Panasonic, and Tata Auto Comp through seed marketing, ahead of commercial production. (5) Management highlighted the successful stabilization of the ammonia-to-amines project. (6) The company plans to debottleneck phenol capacity to nearly 400ktpa with an additional investment of around INR700mn to improve capacity utilization and operational efficiency. (7) The INR115bn crore integrated propylene-to-polycarbonate project is progressing as per schedule, with the entire debt funding tied up under a 60:40 debt-equity structure. Around INR1,2bn has been spent so far, while INR1,5-1,6 bn is planned to be invested during FY27. (8) Management expects the peak project cost, including working capital, to be around Rs8,000-8,500 crore, while maintaining a debt-to-equity ratio below 1x. Commercial commissioning of the polycarbonate plant is targeted for H2FY29, followed by the BPA project a few months later.

Exhibit 1: Quarterly Estimates

(INR bn)	Q1FY27	YoY gr. (%)	Q2FY27E	YoY gr. (%)	Q3FY27E	YoY gr. (%)	Q4FY27E	YoY gr. (%)
Sales	25,776	36%	24,396	28%	22,285	13%	21,374	1%
EBITDA	5,402	185%	4,182	105%	2,603	23%	2,282	-39%
Margin (%)	21%		17%		12%		11%	
Adj. PAT	3,450	207%	2,550	115%	1,356	36%	1,075	-51%

Source: Company, PL

Exhibit 2: Q1FY27 Result Overview - Consolidated (Rs mn)

Y/e March	Q1FY27	Q1FY26	YoY gr. (%)	Q1FY27E	% Var.	Q4FY26	QoQ gr. (%)	FY27E	FY26	YoY gr. (%)
Net Sales	25,776	18,899	36.4	21,737	18.6	21,203	21.6	93,830	78,871	19.0
Gross Profit	9,494	5,292	79.4	7,224	31.4	7,407	28.2	30,238	23,442	29.0
Margin (%)	36.8%	28.0%		33.2%		34.9%		32.2%	29.7%	
EBITDA	5,402	1,896	185.0	3,587	50.6	3,760	43.7	14,469	9,807	47.5
Margin (%)	21.0%	10.0%		16.5%		17.7%		15.4%	12.4%	
Other Income	140	246	(43.0)	70	99.9	69	104.2	469	599	(21.6)
Depreciation	637	513	24.2	641	(0.7)	626	1.7	2670	2246	18.9
EBIT	4,905	1,629	201.2	3,016	62.6	3,203	53.2	12,268	8,160	50.4
Interest	229	81	181.8	190	20.7	189	21.2	844	460	83.5
PBT before exceptional items	4,676	1,547	202.2	2,826	65.5	3,014	55.2	11,424	7,699	48.4
Total Tax	1,226	425	188.6	521	135.5	815	50.4	2,993	2,064	45.0
ETR (%)	26.2%	27.5%		18.4%		27.1%		26.2%	26.8%	
Adj. PAT	3,450	1,123	207.4	2,306	49.6	2,198	56.9	8,431	5,635	49.6
Exceptional Items	0	0		0		0		0	128	
PAT	3,450	1,123	207.4	2,306	49.6	2,198	56.9	8,431	5,507	53.1


Source: Company, PL

Exhibit 3: Q1FY27 - Segmental Performance (Rs mn)

Y/e March	Q1FY27	Q1FY26	YoY gr.	Q4FY26	QoQ gr.	FY27E	FY26	YoY gr.
Advanced Intermediates	8,039	6,053	32.8%	7,077	13.6%	28,731	25,533	12.5%
Phenolics	17,751	13,040	36.1%	14,295	24.2%	65,799	54,006	21.8%
Less Intersegment:	13	194.1	-93.3%	168		700	669	4.6%
Total Revenue	25,776	18,899		21,203		93,830	78,870	19.0%
Advanced Intermediates	670	355	88.8%	336	99.5%	2,011	1,070	88.0%
Phenolics	4178	1179	254.3%	2866	45.8%	9,788	6,946	40.9%
Interest	229	81	181.8%	189	21.2%	844	460	83.5%
Other unallocable expenses	-58	-95	-38.9%	-1	5172.7%	469	-144.2	-425.3%
Exceptional item				-			128	
Total EBT	4,676	1,547	202.2%	3,014	55.2%	11,424	7,571	50.9%
EBIT Margins								
Advanced Intermediates	8.3%	5.9%		4.7%		7.0%	4.2%	
Phenolics	23.5%	9.0%		20.0%		14.9%	12.9%	


Source: Company, PL

Exhibit 4: Revenue to grow at 14% CAGR in FY26-28E




Source: Company, PL

Exhibit 5: AI EBIT margin to be at 7.5% in FY28E




Source: Company, PL

Exhibit 6: Phenolics EBIT to be at Rs10.5/kg in FY28E




Source: Company, PL

Exhibit 7: Return ratios to hover at 7-11%




Source: Company, PL

Exhibit 8: Capex not in sync with FCF



Source: Company, PL

Exhibit 9: PAT margin at 7.3% in FY28E



Source: Company, PL

Financials

Income Statement (INR mn)

Y/e Mar	FY25	FY26	FY27E	FY28E
Net Revenues	82,819	78,871	93,830	102,210
YoY gr. (%)	7.8	(4.8)	19.0	8.9
Cost of Goods Sold	57,879	55,429	63,481	70,056
Gross Profit	24,940	23,442	30,350	32,154
Margin (%)	30.1	29.7	32.3	31.5
Employee Cost	3,922	4,232	4,697	5,214
Other Expenses	10,101	9,403	11,072	12,061
EBITDA	10,918	9,807	14,580	14,879
YoY gr. (%)	(2.8)	(10.2)	48.7	2.0
Margin (%)	13.2	12.4	15.5	14.6
Depreciation and Amortization	1,954	2,246	2,782	3,782
EBIT	8,964	7,561	11,799	11,097
Margin (%)	10.8	9.6	12.6	10.9
Net Interest	275	460	844	1,500
Other Income	839	599	469	511
Profit Before Tax	9,528	7,571	11,424	10,108
Margin (%)	11.5	9.6	12.2	9.9
Total Tax	2,554	2,064	2,993	2,648
Effective Tax Rate (%)	26.8	27.3	27.0	27.0
Profit After Tax	6,974	5,507	8,431	7,460
Minority Interest	-	-	-	-
Share Profit from Associate	-	-	-	-
Adjusted PAT	6,974	5,379	8,431	7,460
YoY gr. (%)	(14.0)	(22.9)	56.7	(11.5)
Margin (%)	8.4	6.8	9.0	7.3
Extra Ord. Income / (Exp)	-	128	-	-
Reported PAT	6,974	5,507	8,431	7,460
YoY gr. (%)	(14.0)	(21.0)	53.1	(11.5)
Margin (%)	8.4	7.0	9.0	7.3
Other Comprehensive Income	-	-	-	-
Total Comprehensive Income	6,974	5,507	8,431	7,460
Equity Shares O/s (mn)	136	136	136	136
EPS (INR)	51.1	39.4	61.8	54.7

Source: Company, PL

Balance Sheet (INR mn)

Y/e Mar	FY25	FY26	FY27E	FY28E
Non-Current Assets				
Gross Block	35,262	45,632	65,632	85,632
Tangibles	35,262	45,632	65,632	85,632
Intangibles	-	-	-	-
Acc: Dep / Amortization	10,717	12,963	15,745	19,526
Tangibles	10,717	12,963	15,745	19,526
Intangibles	-	-	-	-
Net Fixed Assets	24,546	32,669	49,887	66,106
Tangibles	24,546	32,669	49,887	66,106
Intangibles	-	-	-	-
Capital Work In Progress	16,491	18,282	28,282	38,282
Goodwill	27	27	-	-
Non-Current Investments	5,109	2,133	2,133	2,133
Net Deferred Tax Assets	(2,128)	(2,467)	(2,467)	(2,467)
Other Non-Current Assets	-	-	-	-
Current Assets				
Investments	-	-	-	-
Inventories	9,264	8,623	10,856	11,963
Trade Receivables	12,738	15,056	15,424	16,802
Cash & Bank Balance	4,066	2,690	3,831	1,938
Other Current Assets	4,937	7,328	8,718	9,496
Total Assets	77,177	86,807	119,131	146,719
Equity				
Equity Share Capital	273	273	273	273
Other Equity	53,614	58,096	65,482	72,018
Total Network	53,887	58,368	65,755	72,291
Non-Current Liabilities				
Long Term Borrowings	12,591	16,287	40,000	60,000
Provisions	-	-	-	-
Other Non Current Liabilities	-	-	-	-
Current Liabilities				
ST Debt / Current of LT Debt	-	-	-	-
Trade Payables	5,218	5,341	6,129	6,754
Other Current Liabilities	2,993	4,018	4,780	5,207
Total Equity & Liabilities	77,177	86,482	119,131	146,719

Source: Company, PL

Cash Flow (INR mn)

Y/e Mar	FY25	FY26	FY27E	FY28E
PBT	9,528	7,591	11,424	10,108
Add. Depreciation	1,954	2,246	2,782	3,782
Add. Interest	275	460	844	1,500
Less Financial Other Income	839	599	469	511
Add. Other	(560)	(273)	-	-
Op. Profit before WC Changes	11,196	10,025	15,049	15,390
Net Changes-WC	(2,798)	(2,728)	(2,442)	(2,211)
Direct Tax	(2,152)	(1,887)	(2,993)	(2,648)
Net Cash from Op. Activities	6,247	5,410	9,615	10,531
Capital Expenditures	(11,049)	(11,831)	(30,000)	(30,000)
Interest / Dividend Income	337	167	-	-
Others	(4,201)	4,977	-	-
Net Cash from Inv. Activities	(14,913)	(6,687)	(30,000)	(30,000)
Issue of Share Cap. / Premium	102	-	-	-
Debt Changes	8,069	1,498	23,713	20,000
Dividend Paid	(1,023)	(1,023)	(1,044)	(924)
Interest Paid	(194)	(384)	(844)	(1,500)
Others	1,108	1,843	-	-
Net Cash from Fin. Activities	8,062	1,934	21,824	17,576
Net Change in Cash	(605)	657	1,439	(1,893)
Free Cash Flow	(4,802)	(6,422)	(20,385)	(19,469)

Source: Company, PL

Quarterly Financials (INR mn)


Y/e Mar	Q2FY26	Q3FY26	Q4FY26	Q1FY27
Net Revenues	19,019	19,750	21,203	25,776
YoY gr. (%)	(6.4)	3.8	(2.7)	36.4
Raw Material Expenses	13,774	14,252	13,796	16,282
Gross Profit	5,245	5,498	7,407	9,494
Margin (%)	27.6	27.8	34.9	36.8
EBITDA	2,043	2,109	3,760	5,402
YoY gr. (%)	(31.3)	25.1	18.8	185.0
Margin (%)	10.7	10.7	17.7	21.0
Depreciation / Depletion	533	576	626	637
EBIT	1,510	1,534	3,134	4,765
Margin (%)	7.9	7.8	14.8	18.5
Net Interest	79	110	189	229
Other Income	200	85	69	140
Profit before Tax	1,630	1,508	3,014	4,676
Margin (%)	8.6	7.6	14.2	18.1
Total Tax	443	415	815	1,226
Effective Tax Rate (%)	27.2	27.5	27.1	26.2
Profit After Tax	1,188	1,093	2,198	3,450
Minority Interest	-	-	-	-
Share Profit from Associate	-	-	-	-
Adjusted PAT	1,188	1,093	2,198	3,450
YoY gr. (%)	(38.9)	11.4	8.6	207.4
Margin (%)	6.2	5.5	10.4	13.4
Extra Ord. Income / (Exp)	-	-	-	-
Reported PAT	1,188	1,093	2,198	3,450
YoY gr. (%)	(38.9)	11.4	8.6	207.4
Margin (%)	6.2	5.5	10.4	13.4
Other Comprehensive Income	-	-	-	-
Total Comprehensive Income	1,188	1,093	-	-
Avg. Shares O/s (mn)	136	136	136	136
EPS (INR)	8.7	8.0	16.2	25.4

Source: Company, PL

Key Financial Metrics

Y/e Mar	FY25	FY26	FY27E	FY28E
Per Share (INR)				
EPS	51.1	39.4	61.8	54.7
CEPS	65.5	55.9	82.2	82.4
BVPS	395.1	427.9	482.1	530.0
FCF	(35.2)	(47.1)	(149.5)	(142.7)
DPS	8.0	5.0	7.7	6.8
Return Ratio (%)				
RoCE	15.4	10.7	13.1	9.3
ROIC	12.2	8.2	10.0	7.1
RoE	13.7	9.6	13.6	10.8
Balance Sheet				
Net Debt : Equity (x)	0.2	0.2	0.6	0.8
Net Working Capital (Days)	74	85	78	79
Valuation (x)				
PER	34.2	44.3	28.3	32.0
P/B	4.4	4.0	3.6	3.3
P/CEPS	26.7	31.3	21.2	21.2
EV/EBITDA	22.6	25.7	18.8	19.9
EV/Sales	2.9	3.1	2.9	2.9
Dividend Yield (%)	0.4	0.2	0.4	0.3
FCFF Yield (%)	(2.1)	(2.7)	(8.6)	(8.2)
PEG Ratio	(2.5)	(2.0)	0.4	(2.8)

Source: Company, PL

Price Chart

Recommendation History

No.	Date	Rating	TP (INR)	Share Price (INR)
1	07-Jul-26	REDUCE	1514	1613
2	18-May-26	REDUCE	1495	1749
3	13-Apr-26	REDUCE	1354	1473
4	09-Apr-26	HOLD	1408	1423
5	14-Feb-26	Hold	1673	1634
6	07-Jan-26	Hold	1729	1626
7	14-Nov-25	Hold	1768	1741
8	07-Oct-25	Hold	1924	1844
9	14-Aug-25	Hold	1883	1831
10	07-Jul-25	Reduce	1799	1963

Analyst Coverage Universe

Sr. No.	Company Name	Rating	TP (INR)	Share Price (INR)
1	Aarti Industries	Accumulate	526	489
2	Bharat Petroleum Corporation	HOLD	305	310
3	Bharti Airtel	BUY	2275	1978
4	Clean Science and Technology	HOLD	745	734
5	Deepak Nitrite	REDUCE	1514	1613
6	Fine Organic Industries	BUY	6001	5000
7	GAIL (India)	BUY	206	181
8	Gujarat Energy	Hold	293	286
9	Gujarat Fluorochemicals	HOLD	3772	3961
10	Gujarat State Petronet	Hold	242	236
11	Hindustan Petroleum Corporation	Reduce	350	385
12	Indian Oil Corporation	Accumulate	147	140
13	Indraprastha Gas	BUY	181	152
14	Jubilant Ingrevia	Hold	711	745
15	Laxmi Organic Industries	Reduce	169	182
16	Mahanagar Gas	Accumulate	1254	1121
17	Mangalore Refinery & Petrochemicals	HOLD	150	157
18	Navin Fluorine International	Accumulate	8377	7610
19	NOCIL	HOLD	179	171
20	Oil & Natural Gas Corporation	Accumulate	273	240
21	Oil India	Accumulate	455	423
22	P.I. Industries	Hold	2792	2648
23	Petronet LNG	Accumulate	300	280
24	Reliance Industries	BUY	1675	1327
25	SRF	Reduce	2482	2632
26	Sudeep Pharma	Reduce	855	959
27	Vinati Organics	Accumulate	1443	1296

PL's Recommendation Nomenclature (Absolute Performance)

BUY	: > 15%
Accumulate	: 5% to 15%
Hold	: +5% to -5%
Reduce	: -5% to -15%
Sell	: < -15%
Not Rated (NR)	: No specific call on the stock
Under Review (UR)	: Rating likely to change shortly

ANALYST CERTIFICATION

Indian Clients

We/I Mr. Swarnendu Bhushan IIT, MBA Finance, Mr. Saurabh Ahire MBA, Passed CFA Level II, Mr. Tejas Kadam BCom Research Analysts, authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report.

US Clients

The research analysts, with respect to each issuer and its securities covered by them in this research report, certify that: All of the views expressed in this research report accurately reflect his or her or their personal views about all of the issuers and their securities; and No part of his or her or their compensation was, is or will be directly related to the specific recommendation or views expressed in this research report.

Prabhudas Lilladher Pvt. Ltd.

Corporate Office: 6th Floor, Tower 2B South Annex, One World Centre, 841, Senapati Bapat Marg, Lower Parel, Mumbai - 400013

Registered Office: 3rd Floor, Sadhana House, 570, P. B. Marg, Worli, Mumbai-400 018

Tel: (91 22) 6632 2222 Fax: (91 22) 6632 2209

www.plindia.com

DISCLAIMER

Indian Clients

Prabhudas Lilladher Pvt. Ltd, Mumbai, India (hereinafter referred to as "PL") is engaged in the business of Stock Broking, Portfolio Manager, Depository Participant and distribution for third party financial products. PL is a subsidiary of Prabhudas Lilladher Advisory Services Pvt Ltd, which has its various subsidiaries engaged in business of commodity broking, investment banking, financial services (margin funding) and distribution of third party financial/other products, details in respect of which are available at www.plindia.com.

This document has been prepared by the Research Division of PL and is meant for use by the recipient only as information and is not for circulation. This document is not to be reported or copied or made available to others without prior permission of PL. It should not be considered or taken as an offer to sell or a solicitation to buy or sell any security.

The information contained in this report has been obtained from sources that are considered to be reliable. However, PL has not independently verified the accuracy or completeness of the same. Neither PL nor any of its affiliates, its directors or its employees accepts any responsibility of whatsoever nature for the information, statements and opinion given, made available or expressed herein or for any omission therein.

Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The suitability or otherwise of any investments will depend upon the recipients particular circumstances and, in case of doubt, advice should be sought from an independent expert/advisor.

Either PL or its affiliates or its directors or its employees or its representatives or its clients or their relatives may have position(s), make market, act as principal or engage in transactions of securities of companies referred to in this report and they may have used the research material prior to publication.

PL may from time to time solicit or perform investment banking or other services for any company mentioned in this document.

PL is a registered with SEBI under the SEBI (Research Analysts) Regulation, 2014 and having registration number INH000000271.

PL submits that no material disciplinary action has been taken on us by any Regulatory Authority impacting Equity Research Analysis activities.

PL or its research analysts or its associates or his relatives do not have any financial interest in the subject company.

PL or its research analysts or its associates or his relatives do not have any material conflict of interest at the time of publication of the research report.

PL or its associates might have received compensation from the subject company in the past twelve months.

PL or its research analysts or its associates or his relatives do not have actual/beneficial ownership of one per cent or more securities of the subject company at the end of the month immediately preceding the date of publication of the research report.

PL or its associates might have managed or co-managed public offering of securities for the subject company in the past twelve months or mandated by the subject company for any other assignment in the past twelve months.

PL or its associates might have received any compensation for investment banking or merchant banking or brokerage services from the subject company in the past twelve months.

PL or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past twelve months

PL or its associates might have received any compensation or other benefits from the subject company or third party in connection with the research report.

PL encourages independence in research report preparation and strives to minimize conflict in preparation of research report.

PL or its analysts did not receive any compensation or other benefits from the subject Company or third party in connection with the preparation of the research report.

PL or its Research Analysts do not have any material conflict of interest at the time of publication of this report.

It is confirmed that Mr. Swarnendu Bhushan IIT, MBA Finance, Mr. Saurabh Ahire MBA, Passed CFA Level II, Mr. Tejas Kadam BCom Research Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

The Research analysts for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

The research analysts for this report has not served as an officer, director or employee of the subject company PL or its research analysts have not engaged in market making activity for the subject company

Our sales people, traders, and other professionals or affiliates may provide oral or written market commentary or trading strategies to our clients that reflect opinions that are contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest.

PL and its associates, their directors and employees may (a) from time to time, have a long or short position in, and buy or sell the securities of the subject company or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company or act as an advisor or lender/borrower to the subject company or may have any other potential conflict of interests with respect to any recommendation and other related information and opinions.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors

US Clients

This research report is a product of Prabhudas Lilladher Pvt. Ltd., which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of FINRA or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution by Prabhudas Lilladher Pvt. Ltd. only to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor.

In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors, Prabhudas Lilladher Pvt. Ltd. has entered into an agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo").

Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.